Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial

In a randomized controlled trial Tim Davis and colleagues investigate Artemisinin-naphthoquine versus artemether-lumefantrine for the treatment of P. falciparum and P. vivax malaria. Please see later in the article for the Editors' Summary

[1]  P. Siba,et al.  Effect of Coadministered Fat on the Tolerability, Safety, and Pharmacokinetic Properties of Dihydroartemisinin-Piperaquine in Papua New Guinean Children with Uncomplicated Malaria , 2014, Antimicrobial Agents and Chemotherapy.

[2]  S. Nair,et al.  Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria , 2014, The Cochrane database of systematic reviews.

[3]  B. Lell,et al.  The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data , 2013, PLoS medicine.

[4]  Heng-lin Yang,et al.  Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China , 2013, Malaria Journal.

[5]  P. Siba,et al.  Pharmacokinetic Properties of Single-Dose Primaquine in Papua New Guinean Children: Feasibility of Abbreviated High-Dose Regimens for Radical Cure of Vivax Malaria , 2013, Antimicrobial Agents and Chemotherapy.

[6]  E. Tjitra,et al.  Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia , 2012, Malaria Journal.

[7]  P. Siba,et al.  Pharmacokinetic Comparison of Two Piperaquine-Containing Artemisinin Combination Therapies in Papua New Guinean Children with Uncomplicated Malaria , 2012, Antimicrobial Agents and Chemotherapy.

[8]  W. Crumb,et al.  In Vitro Cardiovascular Effects of Dihydroartemisin-Piperaquine Combination Compared with Other Antimalarials , 2012, Antimicrobial Agents and Chemotherapy.

[9]  P. Siba,et al.  Artemisinin-Naphthoquine Combination Therapy for Uncomplicated Pediatric Malaria: a Tolerability, Safety, and Preliminary Efficacy Study , 2012, Antimicrobial Agents and Chemotherapy.

[10]  P. Siba,et al.  Artemisinin-Naphthoquine Combination Therapy for Uncomplicated Pediatric Malaria: a Pharmacokinetic Study , 2012, Antimicrobial Agents and Chemotherapy.

[11]  Nancy Fullman,et al.  Global malaria mortality between 1980 and 2010: a systematic analysis , 2012, The Lancet.

[12]  F. Nosten,et al.  Randomized, Double-Blind, Placebo-Controlled Trial of Monthly versus Bimonthly Dihydroartemisinin-Piperaquine Chemoprevention in Adults at High Risk of Malaria , 2012, Antimicrobial Agents and Chemotherapy.

[13]  A. Rosanas-Urgell,et al.  Features and Prognosis of Severe Malaria Caused by Plasmodium falciparum, Plasmodium vivax and Mixed Plasmodium Species in Papua New Guinean Children , 2011, PloS one.

[14]  M. Ackerman,et al.  QTc Values Among Children and Adolescents Presenting to the Emergency Department , 2011, Pediatrics.

[15]  M. Ramharter,et al.  Pyronaridine–artesunate combination therapy for the treatment of malaria , 2011, Current opinion in infectious diseases.

[16]  P. Siba,et al.  Population Pharmacokinetics of Artemether, Lumefantrine, and Their Respective Metabolites in Papua New Guinean Children with Uncomplicated Malaria , 2011, Antimicrobial Agents and Chemotherapy.

[17]  P. Siba,et al.  Reference intervals for common laboratory tests in Melanesian children. , 2011, The American journal of tropical medicine and hygiene.

[18]  P. Siba,et al.  Characterization of Treatment Failure in Efficacy Trials of Drugs against Plasmodium vivax by Genotyping Neutral and Drug Resistance-Associated Markers , 2011, Antimicrobial Agents and Chemotherapy.

[19]  P. Siba,et al.  Desbutyl-Lumefantrine Is a Metabolite of Lumefantrine with Potent In Vitro Antimalarial Activity That May Influence Artemether-Lumefantrine Treatment Outcome , 2011, Antimicrobial Agents and Chemotherapy.

[20]  F. Hombhanje,et al.  Artemisinin-Naphthoquine Combination (ARCO®): An Overview of the Progress , 2010, Pharmaceuticals.

[21]  P. Siba,et al.  In vitro sensitivity of Plasmodium falciparum to conventional and novel antimalarial drugs in Papua New Guinea , 2010, Tropical medicine & international health : TM & IH.

[22]  P. Siba,et al.  A trial of combination antimalarial therapies in children from Papua New Guinea. , 2008, The New England journal of medicine.

[23]  J. Baird.  Real-world therapies and the problem of vivax malaria. , 2008, The New England journal of medicine.

[24]  Nicholas J White,et al.  Vivax malaria: neglected and not benign. , 2007, The American journal of tropical medicine and hygiene.

[25]  P. Siba,et al.  Pharmacokinetics and Efficacy of Piperaquine and Chloroquine in Melanesian Children with Uncomplicated Malaria , 2007, Antimicrobial Agents and Chemotherapy.

[26]  N. White.  Cardiotoxicity of antimalarial drugs. , 2007, The Lancet. Infectious diseases.

[27]  Pratap Singhasivanon,et al.  How much fat is necessary to optimize lumefantrine oral bioavailability? , 2007, Tropical medicine & international health : TM & IH.

[28]  F. Hombhanje,et al.  Impact of pre-packaging antimalarial drugs and counselling on compliance with malaria treatment at Port Moresby General Hospital Adult Outpatient Department. , 2006, Papua and New Guinea medical journal.

[29]  C. Shan,et al.  Naphthoquine phosphate and its combination with artemisinine. , 2004, Acta tropica.

[30]  S. Satpathy,et al.  Severe falciparum malaria , 2004, Indian journal of pediatrics.

[31]  S. Hewitt,et al.  Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. , 2003, British journal of clinical pharmacology.

[32]  T. Davis,et al.  Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. , 2003, British journal of clinical pharmacology.

[33]  G. Brittenham,et al.  Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand. , 2003, The Southeast Asian journal of tropical medicine and public health.

[34]  A. Hubbard,et al.  Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. , 2003, The American journal of tropical medicine and hygiene.

[35]  M. V. van Agtmael,et al.  Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. , 1999, International journal of antimicrobial agents.

[36]  J. Karbwang,et al.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. , 1998, British journal of clinical pharmacology.

[37]  T. Davis,et al.  In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. , 1996, International journal for parasitology.

[38]  S. Nagase,et al.  [PCR-RFLP analysis]. , 1996, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[39]  B. Diquet,et al.  The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects. , 1994, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[40]  L F Burmeister,et al.  Proving the Null Hypothesis , 1992, Infection Control & Hospital Epidemiology.

[41]  W C Blackwelder,et al.  "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.

[42]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[43]  T. Davis,et al.  Piperaquine , 2005, Drugs.

[44]  R. Snow,et al.  Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria , 2003 .

[45]  I. Felger,et al.  Genotyping of Plasmodium falciparum. PCR-RFLP analysis. , 2002, Methods in molecular medicine.

[46]  Econor,et al.  ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS , 2002 .

[47]  I. Felger,et al.  Genotyping of Plasmodium falciparum , 2002 .

[48]  K. Mendis,et al.  The neglected burden of Plasmodium vivax malaria. , 2001, The American journal of tropical medicine and hygiene.

[49]  Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[50]  M. Ashton,et al.  Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[51]  J. Bartko.  Proving the null hypothesis. , 1991 .

[52]  M. Palmer.  Clinical Trials: A Practical Approach , 1985 .